Coincides with launch of first social listening and sentiment analysis platform allowing researchers and pharma developers to tune into the cancer conversation with verified oncologists on Twitter
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.
Well-established biomarkers in breast cancer today include BRCA1/BRCA2, estrogen and progesterone receptors as well as p53, which is the most studied biomarker in breast cancer. Let’s look at some of the biomarkers that are emerging in this space.
Larvol, a San Francisco-based pharma SaaS (Software as a Service) company, announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the Medical Affairs Professional Society Annual Conference in New Orleans, LA.